Also found in: Wikipedia.



Pharmacologic class: Interleukin-1 (IL-1) blocker

Therapeutic class: Immunomodulator, antirheumatic

Pregnancy risk category B


Inhibits binding of IL-1 with IL type I receptors, thereby mediating immunologic, inflammatory, and other physiologic responses


Prefilled glass syringes: 100 mg/0.67 ml

Indications and dosages

Moderately to severely active rheumatoid arthritis in patients ages 18 and older who don't respond to disease-modifying antirheumatics alone

Adults: 100 mg/day subcutaneously, given at same time each day


• Hypersensitivity to drug or Escherichia coli-derived protein

• Serious infections


Use cautiously in:

• immunosuppression, active infection, chronic illness, renal impairment

• elderly patients

• pregnant or breastfeeding patients

• children.


Withhold drug and notify prescriber if patient shows signs or symptoms of active infection.

Use extreme caution if patient is concurrently receiving drugs that block tumor necrosis factor (TNF), because of increased risk of serious infection.

• Give entire dose from prefilled syringe.

• Don't freeze or shake syringe.

Adverse reactions

CNS: headache

EENT: sinusitis

GI: nausea, diarrhea, abdominal pain

Hematologic: thrombocytopenia, neutropenia

Respiratory: upper respiratory tract infection

Skin: rash, pruritus, injection site reaction or bruising, rash, erythema, inflammation

Other: flulike symptoms, infections


Drug-drug. Etanercept, infliximab, other drugs that block TNF: increased risk of serious infection

Live-virus vaccines: vaccine inefficacy

Drug-diagnostic tests. Neutrophils: decreased count

Patient monitoring

• Monitor CBC with white cell differential.

• Assess injection site for reactions.

Patient teaching

Tell patient to immediately report signs or symptoms of infection.

• Advise patient to report signs and symptoms of allergic response.

• Instruct patient to take drug at same time each day for best response.

• Teach patient about proper drug disposal (in puncture-resistant container). Also caution him against reusing needles, syringes, and drug product.

• Tell patient not to freeze or shake drug.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


an antirheumatic agent and immunomodulator used to reduce the signs and symptoms of moderate to severe active rheumatoid arthritis in adults.


A human INTERLEUKIN-1-receptor antagonist used to combat the pro-inflammatory interleukins in RHEUMATOID ARTHRITIS. A brand name is Kineret.
References in periodicals archive ?
Contract award notice: Pnsp 65/2017 - acquisition of medicines: Nitisinone, Sodium phenylbutyrate, Anakinra and efmoroctocog alfa
M2 EQUITYBITES-November 16, 2017-Sobi investigates the safety and efficacy of anakinra in patient with Still's disease under phase 3 clinical study
M2 PHARMA-November 16, 2017-Sobi investigates the safety and efficacy of anakinra in patient with Still's disease under phase 3 clinical study
The new medications being studied are anakinra, an interleukin 1 Beta recombinant receptor antagonist, and canakinumab, another interleukin receptor blocker.
We report using anti-interleukin-1 agents anakinra and canakinumab in four colchicine-resistant patients who were successfully treated.
Keywords: Anakinra, DMARDs, NSAIDs, Rheumatoid arthritis, Tocilizumab.
sup][6] It seems that the effective treatment options are very limited merely targeting at IL-1 receptor or IL-1[sz] including anakinra which is a short-acting IL-1 receptor antagonist, canakinumab which is a fully human monoclonal antibody providing selective and prolonged IL-1[sz] blockade, and rilonacept which is an IL-1 trap fusion protein.
Anakinra could make the sisters, of Morcambe, Lancs, pain-free, but is not prescribed on the NHS due to its PS10,000 a year cost.
16) Anakinra may have a role in controlling flairs of CPPD when conventional therapies are contraindicated or ineffective.
She's taking daily injections of Kineret -generically Anakinra - "and it has really given me my life back," Chambers said.
In addition, Sobi has been granted a US patent for acitrate- free formulation of anakinra which will expire in 2032.